SLAM
DFTX

Swiss Life Asset Management’s Definium Therapeutics DFTX Stock Holding History

Swiss Life Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
5,637
-12,108
-68% -$299K ﹤0.01% 1348
2026
Q1 		$187K Buy
+17,745
New +$301K ﹤0.01% 1402

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Swiss Life Asset Management's DFTX Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Definium Therapeutics (DFTX) stake by 68% in Q2 2026, selling an estimated $299K and leaving 5,637 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1348.

Swiss Life Asset Management first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Swiss Life Asset Management held 5,637 shares of Definium Therapeutics worth $265K as of Q2 2026.
  • Swiss Life Asset Management sold 12,108 Definium Therapeutics shares in Q2 2026, an estimated $299K.
  • Definium Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1348 holding.
  • Swiss Life Asset Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.